A drug for our times? New Dapagliflozin indication: reducing risk of hospitalisation

2 minute read


The availability of commonly used antihyperglycemic therapies in type 2 diabetes have, as yet, failed to make any substantial impact upon preventing heart failure and hospitalisations for this condition continue unabated


This content is for AHPRA registered professionals only.
Join Now

End of content

No more pages to load

Log In Register ×